Disease/Infection News

RSS

Heidelberg University scientists gain new insight into cytotoxic effect of Ebola virus

In the course of basic research in membrane biochemistry scientists at Heidelberg University have gained new insight into the cytotoxic effect of the Ebola virus. Employing biochemical and cell biological methods they have shed light on the molecular relationships between the Ebola glycoprotein and its role in mediating cytotoxicity.

22 Jul 2015

Researchers report new drug combination that effectively treats HCV patients co-infected with HIV

Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV.

22 Jul 2015

AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

In a phase 2 trial that included nearly 1,000 adults, the AS03 and MF59 adjuvants (a component that improves immune response of inactivated influenza vaccines) increased the immune responses to two doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest amount of antibody response, according to a study in the July 21 issue of JAMA.

22 Jul 2015

Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

A Phase III, individually randomized trial has found conditional cash transfers for school attendance did not reduce the risk of HIV among high-school aged women in South Africa, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

22 Jul 2015

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic and diagnostic solutions for major infectious and chronic diseases, today announced the overall results of its Phase I/IIa clinical study of its VAC-3S immunotherapy, which is currently in development.

22 Jul 2015

Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

The negative health effects of international air travel are well documented but now it seems that the common elderberry can provide some relief.

22 Jul 2015

Researchers devise way to induce protective immunity in mice against influenza viruses

A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain.

22 Jul 2015

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals.

22 Jul 2015

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection--an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing.

22 Jul 2015

Synthetic sugar could be latest weapon against superbugs

A special type of synthetic sugar could be the latest weapon in the fight against superbugs. A team of scientists from The University of Queensland and Queensland biotechnology company Alchemia have discovered a potential new class of antibiotics inspired by sugar molecules produced by bacteria.

22 Jul 2015

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance today announces that the first group of healthy male volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3, for use in the treatment of Clostridium difficile infections.

21 Jul 2015

TGen, NAU to jointly develop quick, affordable and accurate test to diagnose Lyme disease

Focus On Lyme, an initiative sponsored by the Leadership Children's Foundation of Gilbert, Ariz., has donated $75,000 to the Translational Genomics Research Institute to support research into the development of a quick, affordable and accurate method of diagnosing Lyme disease.

21 Jul 2015

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

21 Jul 2015

New drug cures malaria in mice

A new drug acts as a roadblock for malaria, curing mice of established infection, according to a study in The Journal of Experimental Medicine. Treatment was not associated with obvious side effects, suggesting that the drug may also be safe and effective in humans.

21 Jul 2015

NDSU assistant professor receives NIH grant to study regulation of transporters in Gram-negative bacteria

Christopher Colbert, assistant professor of biochemistry at North Dakota State University, Fargo, has received a $348,000 grant award from the National Institute of General Medical Sciences of the National Institutes of Health to conduct research on structure-function relationships of iron transport and transcriptional regulation in Gram-negative bacteria.

20 Jul 2015

Study findings provide basis for potential development of new methods to control HIV infection

Lower levels of cholesterol in certain immune cells--a result of enhanced cholesterol metabolism within those cells--may help explain why some HIV-infected people are able to naturally control disease progression, according to research that will be presented in a poster at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, and the pre-conference 2015 Towards an HIV Cure Symposium.

20 Jul 2015

Scientists find potent agent that thwarts drug resistance in malaria parasite

Scientists have made an important breakthrough in the fight against malaria, identifying a potent agent that thwarts drug resistance in the parasite that causes the disease.

20 Jul 2015

Chicago creates sustainable network to meet complicated public health emergencies

The Ebola epidemic and resulting international public health emergency is referred to as a "Black Swan" event in medical circles because of its unpredictable and impactful nature. However, a paper in the June 30 issue of Clinical Infectious Diseases, a leading journal in the field of infectious diseases, suggests that the response of the Chicago Ebola Response Network (CERN) in 2014-2015 has laid a foundation and a roadmap for how a regional public health network can anticipate, manage and prevent the next Black Swan public health event.

17 Jul 2015

Virginia Tech scientist uses mathematical model to show how bacteria can control behavior of robots

Forget the Vulcan mind-meld of the Star Trek generation -- as far as mind control techniques go, bacteria is the next frontier. In a paper published July 16 in Scientific Reports, which is part of the Nature Publishing Group, a Virginia Tech scientist used a mathematical model to demonstrate that bacteria can control the behavior of an inanimate device like a robot.

17 Jul 2015

TSRI scientists awarded two grants to develop new therapeutic target to reduce latent HIV infection

Scientists from the Florida campus of The Scripps Research Institute have been awarded a pair of grants totaling nearly $2.8 million from the National Institute of Allergy and Infectious Diseases of The National Institutes of Health to develop a new therapeutic agent to reduce latent levels of HIV that hide from the immune system in infected individuals.

17 Jul 2015

Disease/Infection News

Heidelberg University scientists gain new insight into cytotoxic effect of Ebola virus

Researchers report new drug combination that effectively treats HCV patients co-infected with HIV

AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

Researchers devise way to induce protective immunity in mice against influenza viruses

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

Synthetic sugar could be latest weapon against superbugs

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

TGen, NAU to jointly develop quick, affordable and accurate test to diagnose Lyme disease

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

New drug cures malaria in mice

NDSU assistant professor receives NIH grant to study regulation of transporters in Gram-negative bacteria

Study findings provide basis for potential development of new methods to control HIV infection

Scientists find potent agent that thwarts drug resistance in malaria parasite

Chicago creates sustainable network to meet complicated public health emergencies

Virginia Tech scientist uses mathematical model to show how bacteria can control behavior of robots

TSRI scientists awarded two grants to develop new therapeutic target to reduce latent HIV infection

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News